119th Congress · introduced in the House · May 14, 2026
Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.
Official title from Congress.gov
Latest action (May 14, 2026): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Submitted in House
Submitted in House
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
9 citations.
POWER TO DECIDE · lobbying firm or registrant: POWER TO DECIDE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · amended · posted Oct 22, 2026 · issue area: Family issues/Abortion/Adoption
$18,176
Spent on own lobbying
…om to Travel for Health Care Act (S. 4701) Reproductive Health Travel Fund Act (H.R. 4625/S. 4922) Resolution Regarding the Safety of Mifepristone (S. Res. 732/H. Res. 1285)
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PLANNED PARENTHOOD FEDERATION OF AMERICA INC · lobbying firm or registrant: PLANNED PARENTHOOD FEDERATION OF AMERICA, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Family issues/Abortion/Adoption
$308,925
Spent on own lobbying
…s governing access medication abortion care should be equitable, transparent, and based on the best available peer-reviewed evidence-based science. (S.Res. 732/H.Res. 1285)
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL COUNCIL OF JEWISH WOMEN · lobbying firm or registrant: NATIONAL COUNCIL OF JEWISH WOMEN
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Family issues/Abortion/Adoption
$10,000
Spent on own lobbying
…41) Support the Reproductive Health Care Accessibility Act of 2026 (HR 8829/S 4540) Support the Resolution Reaffirming that Mifepristone is Safe and Effective (H Res 1285/S Res 732) Support the Freedom to Travel for Health Care Act (S 4701) Support the Let Doctors Provide Reproductive Health Care Act (S 4879) Support the SAFE Tr…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CIVIL LIBERTIES UNION · lobbying firm or registrant: AMERICAN CIVIL LIBERTIES UNION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 19, 2026 · issue area: Civil Rights/Civil Liberties
$950,000
Spent on own lobbying
…Families Act of 2025-Issues Lobbied: Reproductive Rights, Immigrants Rights. H.R. 9432-LIFT the BAR Act-Issues Lobbied: Reproductive Rights, Immigrants Rights. H.Res. 1285-Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
REPRODUCTIVE FREEDOM FOR ALL · lobbying firm or registrant: REPRODUCTIVE FREEDOM FOR ALL
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · amended · posted Aug 12, 2026 · issue area: Family issues/Abortion/Adoption
$30,000
Spent on own lobbying
…ats of force, obstruction, and property damage intended to interfere with reproductive health care services; Access to evidence-based medication abortion care; H.Res.1285 and S.Res.732 expressing the sense of Congress that mifepristone is safe and effective and law and policy governing access to medication abortion care in the U…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
NATIONAL COUNCIL OF JEWISH WOMEN · lobbying firm or registrant: NATIONAL COUNCIL OF JEWISH WOMEN
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Family issues/Abortion/Adoption
$10,000
Spent on own lobbying
…Act Support the Reproductive Health Care Accessibility Act of 2026 (HR 8829/S 4540) Support the Resolution Reaffirming that Mifepristone is Safe and Effective (H Res 1285/S Res 732) Support the Freedom to Travel for Health Care Act (S 4701) Support the Let Doctors Provide Reproductive Health Care Act (S 4879) Support the SAFE Tr…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GUTTMACHER INSTITUTE · lobbying firm or registrant: GUTTMACHER INSTITUTE
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Family issues/Abortion/Adoption
$9,749
Spent on own lobbying
…ss to medication abortion care- met with staff and drafted text -Reproductive Health Travel Fund Act (not yet introduced)- worked on drafting text -S.Res.732 / H.Res.1285 Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
AMERICAN CIVIL LIBERTIES UNION · lobbying firm or registrant: AMERICAN CIVIL LIBERTIES UNION
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Civil Rights/Civil Liberties
$670,000
Spent on own lobbying
…Families Act of 2025-Issues Lobbied: Reproductive Rights, Immigrants Rights. H.R. 9432-LIFT the BAR Act-Issues Lobbied: Reproductive Rights, Immigrants Rights. H.Res. 1285-Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
POWER TO DECIDE · lobbying firm or registrant: POWER TO DECIDE
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Family issues/Abortion/Adoption
$21,703
Spent on own lobbying
…om to Travel for Health Care Act (S. 4701) Reproductive Health Travel Fund Act (H.R. 4625/S. 4922) Resolution Regarding the Safety of Mifepristone (S. Res. 732/H. Res. 1285)
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing